Symptoms and General Pathology

All Conditions

Substance Related Disorders

Behaviors and Mental Disorders

Nervous System Diseases

Rare Diseases

Chronic Pain

Pain

Opioid-Related Disorders

Neurologic Manifestations

Narcotic-Related Disorders

Substance-Related Disorders

Chemically-Induced Disorders

Mental Disorders

Psychotic Disorders

Quality of Life

Chronic Graft Versus Host Disease

Analgesics

Central Nervous System Depressants

All Drugs and Chemicals

Analgesics, Opioid

Patients with chronic non-cancer pain referred to secondary and tertiary care

ASI-SR

Pernilla Åsenlöf, Profesor

The Swedish version of ASI-SR has shown good feasibility in assessment of addiction patients functioning compare to long and time-consuming ASI, which is upp to date golden standard in Sweden. This study investigate if ASI-SR is suitable instrument for the assessment of the chronic pain patient addicted to opioids. The validation process is designed according to the COSMIN guidelines.

Preliminary results are expected by December 2022.

The use of opioids in treatment of chronic non- cancer pain (CNCP) has increased during the past decades in most parts of the western world. Use of prescription opioids can lead to problematic opioid use which can be life-threatening with significant morbidity and mortality. Studies have found that 21-29% of CNCP patients receiving chronic opioid therapy (COT) ( receiving opioids for \> 90 days) have problematic opioid use. Individuals with chronic pain and co-occurring substance use disorders and/or mental health disorders, have increased risk for problematic use of prescribed opioids.

Several screening instruments and strategies have been introduced in recent years for identifying patients not suitable for opioid therapy. Even so, there is no single test or instrument that can reliably identify those patients at risk for developing problematic opioid use or opioid use disorder if opioid therapy is initiated, or identify those who need increased monitoring during treatment.

Addiction Severity Index (ASI) is a standardized semi-structured interview used for assessing severity and need of treatment in seven functional domains associated to substance use disorders; physical health, employment/support status, alcohol use, drug use, legal status, family/social functioning and psychiatric health. The ASI was developed in the US. by McLellan and colleagues and is widely used all over the world, both in research and for clinical assessment and treatment evaluations . The ASI could be a useful instrument for a multidimensional assessment of patients with chronic non-cancer where opioid treatment is considered, and it could also be used for evaluation of ongoing opioid therapy . However, the ASI interview is a time consuming instrument. To conduct an interview takes between 45-60 minutes and is followed by 20-25 minutes of administrative work. In the year of 2000 Rosen et al tested a short self-report form based the items used to calculate the ASI composite scores that asses current function and problem severity. This questionnaire was translated by our research group and tested on a sample of individuals referred to the Addiction clinic at Uppsala University Hospital. The study suggested that a self-administered questionnaire based on the subscales of the ASI composite scores is a feasible alternative to the ASI interview for assessing patient functioning in the different domains and screen for current problematic alcohol- or drug use .

A validated screening tool that provides both an effective method of assessing patients and identifying problems in several different life domains, and identify substance use related problems if they should arise, would be beneficial in clinical practice when deciding what treatment to offer. Such an instrument could potentially decrease the risk of iatrogenic opioid use disorder.

Purpose and aims The main objective with this study is to test the psychometric properties of the ASI-SR in a population of CNCP patients. 'Secondary aim is to describe differences between subjects treated within the substitution therapy program and those who are treated within the pain clinic.

Method:

Sample Participants for this study will be recruited from outpatient pain clinic and addiction clinic at Uppsala University Hospital, and Linköping University Hospital Sweden. Eligible for participation are persons \>18-65 years of age with current CNCP and ongoing treatment at the facilities. Estimated number of participant needed is about 200.

Exclusion criteria are severe cognitive impairment, illiterate in Swedish, and inability to give informed consent.

Procedures Eligible participants will be approached and asked if they can consider to participate in the study by clinical staff at the facilities. If they accept, they will receive an e-mail with a link to the questionnaires and to written information about the study. If they decide to participate they will give informed consent by signing a digital consent form. A digital battery of questionnaires containing the ASI-SR and a validity battery will then be provided to the participants to fill out. The validity battery will consist of self-report forms. To participants that do not respond to the questionnaires and have not declined participation, reminders will be sent out by text-messages, e-mail and mail. Four days after the participants have completed the questionnaires they will receive an e-mail with a link the ASI-SR form to fill out once more to test re-test reliability.

Participants that do not want to or do not have access to the digitalized versions of the questionnaires will be offered to fill out paper versions of the questionnaires sent to them by mail.

Measures ASI-SR is a 38 question self-administered form based on the items used to calculate the ASI's composite scores, measuring current problems and severity in seven domains . The CS ranges from 0 to 1 where 0 indicates no problems.

The validity battery consist of self-administered questionnaires that correspond to six out of seven of the ASI-SR's domains. These questionnaires will be used as concurrent validity measures for all the ASI-SR composite scores (CS) except the CS for legal situation. The participants will fill out questions about current pain intensity and pain interference, the Rand 36 for multidimensional health related quality of life , pain related disability Pain Disability Index (PDI) and Sheehan Disability Scale (SDS) which measures disability across domains of work/school, social life, and family life/home responsibilities . The Alcohol Use Disorder Identification Test (AUDIT) will be used for assessment of problematic alcohol use and the Drug Use Disorder Identification Test (DUDIT) for assessment of problematic illicit drug use . PHQ9 will assess depressive symptoms and the GAD 7 will be used for assessment of anxiety symptoms . Patient global impression of change (P-GIC) will be used to evaluate if the participants experienced any changes in global health between test-retest of the ASI-SR. P-GIC is gold standard for measuring change in CNCP patients .

Statistics Statistical analyses will be done using SPSS (Version 23, IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp). Calculation of the CS follow standard procedure . Consistency of CS between the interview and the self-report will be evaluated on the individual basis by interclass correlation analysis (ICC) and at group level with paired t-test or Wilcoxon signed rank test if data is not normally distributed. ICC coefficient is considered to be poor if it is less than 0.40, fair between 0.40-0.59 , good between 0.60-0.70 and excellent between 0.75-1.00 .

Reliability and internal consistency will be evaluated using Cronbach's α. The α coefficient is considered acceptable if it is above 0.70 .

The concurrent validity of each score will be assessed with suitable correlation analyses between the ASI-SR composite score(s) and the external validity measure(s).

To assess discriminant validity of the ASI-SR composite scores and external validity measures, an intercorrelation matrix between ASI-SR composite scores, and composite scores and external measures will be computed.

For evaluating factor structure principal component analyses (PCA) will be used.

Relevance for the field Opioid therapy for chronic non-cancer pain has emerged as a problematic treatment and the evidence is scarce for its effectiveness . However, there are some individuals that seem to benefit from opioid therapy and most guidelines propose an individual approach to management, beginning with a comprehensive patient evaluation, focusing on factors that may indicate potential substance use disorder. When opioids are used, clinicians should closely monitor patients for loss of response, adverse effects or aberrant behavior, and assess treatment outcome . There is a need for a multi-dimensional instrument that can assess problems related to increased risk for developing problematic opioid use, i.e. opioid use disorder, psychiatric co-morbidity and social problems. The ASI-SR could be an effective way of screening for current problems in different life domains and to monitor and evaluate ongoing treatment and identify problems if they would arise. Additional measures include urine or saliva drug testing, prescription practice, opioid treatment agreements, and universal precautions in conjunction with opioid therapy.

Ethical considerations The study will be sent to the Regional Ethical Review Board in Uppsala. Participants will be anonymous and all data will be coded before processed.

Validation of the ASI-SR Form in a Population of Chronic Non-cancer Pain Patients

ASI-SR Form as a Standardized Instrument for Healthcare Management of Chronic Non-cancer Pain Patients

Age, sex, educational level, occupational status etc For evaluating factor structure principal component analyses (PCA) will be used.

The main objective with this study is to test the psychometric properties of the ASI-SR in a population of CNCP patients.Consistency of CS between the interview and the self-report will be evaluated on the individual basis by interclass correlation analysis (ICC) and at group level with paired t-test or Wilcoxon signed rank test if data is not normally distributed. ICC coefficient is considered to be poor if it is less than 0.40, fair between 0.40-0.59 , good between 0.60-0.70 and excellent between 0.75-1.00.

7-grade scale (-3-+3)where the lowest points indicate negative and highest points indicate positive change.

Second test ASI-SR for reproducibility( 0,1 answer /scores in different categories)

Generalised Anxiety Disorder 7-item scale (0-21) The higher the score the higher severity of the anxiety disorder, cut-off 10.

Quality of life instrument of International Resource Center for Health Care considering both physical and mental health aspects. Scores 0-100. The Higher score the better quality of life in different segments of well-being, function or quality of life.

7-question score system for different pain groups,(0-70). The higher the index the greater the persons disability due to the pain.

Scoring system, (0-40)where increase of the points reflects increased risk of problematic alcohol use.

Scoring system,(0-44) where increase of the points reflects increased probability of drug abuse syndrome.

Depression Assesment scoring system, (0-15) where \<4 is no need of depression treatment, and \>15 identifies need of pharmacologic or other depression treatment

Uppsala University Hospital

Uppsala University

Marijuana Abuse

Marijuana Use

Narcotics

This group can begin using medical marijuana immediately and will participate in the POTS treatment groups.

This group must abstain from marijuana use and will participate in the POTS behavioral treatment alone.

Patients in this group can choose what type, how much, and when to use medical marijuana to use.

Medical Marijuana

Prescription Opioid Taper Support (POTS), a manualized behavioral prescription opioid taper support intervention developed by consultant, will be offered weekly to all participants to support behavioral self-management of pain and structured, voluntary taper of COT dose.

Prescription Opioid Taper Support (POTS)

Jodi Gilman, PhD

Aurora Quaye, MD

Jodi Gilman

This study will use a randomized controlled design to test whether medical marijuana use by adults on high-dose chronic opioid therapy (COT) for chronic non-cancer pain is associated with reduced opioid dose and improved pain intensity and interference when added to a 24-week behavioral intervention (POTS).

This trial is a randomized, six-month study of medical marijuana (MM) on opioid use that will: (1) evaluate whether adults with chronic, non-cancer pain on COT assigned to MM+POTS, compared with those assigned to WL+POTS, have greater reduction in opioid dose and/or pain intensity and interference, (2) assess whether participants assigned to MM+POTS, compared with those assigned to WL+POTS, have improved quality of life, depression, and anxiety; and reduced self-reported opioid dose, (3) evaluate whether those assigned to MM+POTS develop symptoms of CUD and have a reduced number of OUD symptoms over the 24-week intervention, as well as at the 12-month time point.

Participants will be randomly assigned to either an active MM arm (n = 125), or to a waitlist control arm (WLC) (n = 125). Participants will be assessed at baseline, every 4 weeks for 6 months, and at a 12-month follow-up for opioid use, development of CUD, development or resolution of OUD, and neurocognitive performance. Urine collected will be assessed with quantitative assays.

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain

All data, code, and materials used in the analyses can be provided by Jodi Gilman and Massachusetts General Hospital pending scientific review and a completed data use agreement/material transfer agreement beginning one year after publication of the results. Requests for all materials should be submitted to Jodi Gilman at jgilman1@mgh.harvard.edu.

Opioid dose verified by the Prescription Monitoring Program, in morphine milligram equivalents (MME) per day. If participants decide to reduce dose at week 24, we will use the reduced dose even if the new dose cannot be immediately implemented (e.g., due to delays in refilling prescription) to ensure accurate representation of change.

The Pain, Enjoyment, General Activity (PEG) scale will assess pain intensity and interference. The scale ranges from 0-30, with a higher score indicating greater pain intensity and interference. Collected daily by a self-reported online survey.

Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form will assess changes in quality of life measures. The scale ranges from 14 - 70, with a lower score indicating greater dissatisfaction with life.

The 8-item depression subscale of the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 will be used to assess depression symptoms. The scale uses a t-score metric (mean of 50, SD of 10). Higher scores indicate worse depression.

The 7-item anxiety subscale of the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 will be used to assess anxiety symptoms. The scale uses a t-score metric (mean of 50, SD of 10). Higher scores indicate worse anxiety.

The DSM-5 Opioid Use Disorder Checklist will evaluate symptoms of Opioid Use Disorder (number of symptoms). The scale ranges from 0 - 11, with a higher score indicating more severe Opioid Use Disorder.

The DSM-5 Cannabis Use Disorder Checklist will evaluate symptoms of Cannabis Use Disorder (number of symptoms). The scale ranges from 0 - 11, with a higher score indicating more severe Cannabis Use Disorder.

Self-reported opioid dose in morphine milligram equivalents (MME) per day. This is collected daily by a self-reported online survey and averaged over each 4-week interval.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Validation of the ASI-SR Form in a Population of Chronic Non-cancer Pain Patients	NCT04998734	Chronic Pain Opioid-use Diso... Quality of Life Risk Reduction Assessment, Sel...	ASI-SR	18 Years - 65 Years	Uppsala University
Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain	NCT04827992	Opioid Use Pain Marijuana Use	Medical Marijua... Prescription Op...	18 Years - 75 Years	Massachusetts General Hospital
Validation of the ASI-SR Form in a Population of Chronic Non-cancer Pain Patients	NCT04998734	Chronic Pain Opioid-use Diso... Quality of Life Risk Reduction Assessment, Sel...	ASI-SR	18 Years - 65 Years	Uppsala University
Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain	NCT04827992	Opioid Use Pain Marijuana Use	Medical Marijua... Prescription Op...	18 Years - 75 Years	Massachusetts General Hospital

Spots Global Cancer Trial Database for dependence

Every month we try and update this database with for dependence cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for dependence

Every month we try and update this database with for dependence cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for dependence cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.